Kronos Bio, Inc. (KRON) Stock

About Kronos Bio, Inc.

Kronos Bio, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the identification and advancement of innovative therapies for cancer. Its therapeutic strategy centers on modulating dysregulated transcription factors and the intricate transcriptional regulatory networks that fuel oncogenic activity. The company's primary investigational drug, entospletinib (ENTO), is an orally administered, selective inhibitor of spleen tyrosine kinase (SYK), designed for patients with acute myeloid leukemia. A registrational Phase 3 clinical trial is slated to evaluate ENTO in combination with induction chemotherapy for acute myeloid leukemia patients who possess NPM1 mutations. Furthermore, Kronos Bio is progressing KB-0742, an orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor, which is currently undergoing Phase 1/2 clinical assessment for the treatment of MYC-amplified solid tumors. Established in 2017, the company maintains its headquarters in San Mateo, California.

Kronos Bio, Inc. is headquartered in US.

Kronos Bio, Inc. (KRON) stock trades at $0.88 with a market capitalization of $53.65M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.62, reflecting a net loss over the last twelve months, price-to-book of 0.60, price-to-sales of 5.45. Over the past 52 weeks the stock has ranged between $0.65 and $1.46, and currently trades 39.7% below its 52-week high.

On profitability, Kronos Bio, Inc. generates a return on equity (ROE) of -69.80% (negative, reflecting a net loss), return on capital employed of -85.15%, an operating margin of -943.21%, a net profit margin of -874.08%.

Official website: kronosbio.com